Home/CorMedix/Matt David

MD

Matt David

Chief Financial Officer

Therapeutic Areas

Infectious Disease Nephrology

CorMedix Pipeline

Drug	Indication	Phase
DefenCath (taurolidine/heparin)	Prevention of Catheter-Related Bloodstream Infections (CRBSIs) in hemodialysis patients	Phase 3 / NDA Submitted

Leadership Team at CorMedix

Chief Executive Officer

Chief Development Officer

Khosrow Sholehpour

Chief Commercial Officer

Danielle Hallock

General Counsel and Corporate Secretary

View full CorMedix profile